By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.

Moderna Inc agreed to pay US$950 million to settle litigation related to the delivery technology behind its Covid-19 shot, removing a looming financial risk for the struggling vaccine maker.

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery ...

In what it says could be the largest disclosed patent settlement in the pharmaceutical industry, Roivant Sciences Ltd. has reached a potential $2.25 billion settlement with Moderna Inc. over the use ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by ...

The settlement could go as high as $2.25 billion.

Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, ...

Moderna shares rose ​9% on Wednesday after it settled a long-running legal ​battle over the technology that made its COVID-19 ...